Sirnaomics: Clinical Trials

13 trials sponsored by Sirnaomics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 9 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Completed 6, Active not recruiting 1, Terminated 1, Withdrawn 1
Phase 28Completed 5, Recruiting 1, Terminated 1, Withdrawn 1

Follow Sirnaomics: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
STP705 Injection for Submental Fat Reduction
STP705 - Submental Fullness
Phase 2RecruitingSirnaomics302026-07-282026-08-10
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
FXI-GalNAc-siRNA, Placebo - FXI
Phase 1Active not recruitingSirnaomics402023-05-162026-07-29
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
STP705 - Abdominal Obesity
Phase 1CompletedSirnaomics82022-08-012024-03-18
Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Adults With Facial isSCC
STP705 - Facial isSCC
Phase 1 / Phase 2TerminatedSirnaomics92022-08-012026-10-07
A Study of STP707 Administered by IV in Healthy Subjects
STP707 - Healthy Subjects
Phase 1CompletedSirnaomics202022-02-282024-03-18
Safety, Tolerability, Pharmacokinetics, Immunogenicity and Efficacy of STP705 in Adult Patients With Hypertrophic Scars
STP705 - Hypertrophic Scar
Phase 1 / Phase 2WithdrawnSirnaomics2021-12-072026-07-29
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
STP707 - Solid Tumor
Phase 1CompletedSirnaomics502021-11-012026-07-29
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
STP705, Placebo Saline - Squamous Cell Carcinoma in Situ
Phase 2CompletedSirnaomics442021-05-182024-03-18
A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence
STP705, Placebo - Keloid
Phase 2CompletedSirnaomics292021-04-292024-03-19
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
STP705 - Hepatocellular Carcinoma, Liver Metastases
Phase 1CompletedSirnaomics52021-03-012024-03-19
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
STP705 - Basal Cell Carcinoma
Phase 2CompletedSirnaomics322020-12-282026-09-24
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC
STP705 - Bowen's Disease, Cutaneous Squamous Cell Carcinoma in Situ
Phase 1 / Phase 2CompletedSirnaomics252019-03-212022-06-09
A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar
STP705, Placebo - Hypertrophic Scar
Phase 1 / Phase 2CompletedSirnaomics252017-01-012021-11-24

Conditions studied

Cicatrix, Hypertrophic (2)  ·  Bowen's Disease (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Hepatocellular (1)  ·  Cholangiocarcinoma (1)  ·  Keloid (1)  ·  Obesity, Abdominal (1)  ·  Squamous Intraepithelial Lesions (1)

Interventions

Injections (8)

Countries

United States (11)  ·  Australia (1)  ·  Canada (1)  ·  China (1)

Top investigators

Mark Nestor, MD (4)  ·  Francois Lebel, MD (3)  ·  Brenda LaTowsky, MD (2)  ·  Andrae Vandross, MD (1)  ·  Angela Alistar, MD (1)  ·  Anthony El-Khoueiry, MD (1)  ·  Brian Berman, MD, PhD (1)  ·  Brian Jiang, MD (1)  ·  Christina Wu, MD (1)  ·  Conor Steuer, MD (1)  ·  David Goldberg (1)  ·  David Goldberg, MD (1)  ·  Edward Lain, MD (1)  ·  Edward Primka, MD (1)  ·  Girish Munavalli, MD (1)

Results publications

PMID 32889812, PMID 39692702